Possible association between the -2548A/G polymorphism of the leptin gene and olanzapine-induced weight gain

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jan 1;32(1):160-3. doi: 10.1016/j.pnpbp.2007.08.002. Epub 2007 Aug 14.

Abstract

Antipsychotic-induced weight gain has important effects on treatment compliance and long-term health. Several reports have indicated that a -2548A/G single-nucleotide polymorphism (SNP) of the leptin gene is associated with antipsychotic-induced weight gain. We hypothesized that there is a similar relationship between the -2548A/G SNP and olanzapine-induced weight gain. A total of 74 Korean schizophrenic patients were examined. Their weight was measured before starting olanzapine and after long-term treatment lasting for at least 3 months. The weight gain was significantly higher for patients with the AG genotype than for those with the AA genotype (p=0.029). Analysis of covariance also showed the difference of weight gain was still significant when adjusted for sex and treatment duration (p=0.046). This finding supports the presence of a relationship between the -2548A/G SNP of the leptin gene and weight gain in Korean schizophrenic patients receiving olanzapine treatment.

MeSH terms

  • Adult
  • Analysis of Variance
  • Antipsychotic Agents / adverse effects*
  • Benzodiazepines / adverse effects*
  • Body Mass Index
  • Female
  • Gene Frequency
  • Genotype
  • Humans
  • Korea
  • Leptin / genetics*
  • Male
  • Middle Aged
  • Olanzapine
  • Polymorphism, Single Nucleotide / genetics*
  • Schizophrenia / drug therapy
  • Schizophrenia / physiopathology
  • Weight Gain / drug effects*
  • Weight Gain / genetics

Substances

  • Antipsychotic Agents
  • Leptin
  • Benzodiazepines
  • Olanzapine